CD274 and small cell lung carcinoma: Our study also found that the median PFS and OS were 8.2 months and 20.1 months respectively for the patients with ES-SCLC receiving anlotinib plus immunotherapy including PD-1 or PD-L1 inhibitors, which presented statistically significant differences comparing with chemotherapy group.